tradingkey.logo

Ginkgo Bioworks Holdings Inc

DNA
查看詳細走勢圖
8.405USD
-0.505-5.67%
收盤 12/26, 16:00美東報價延遲15分鐘
477.71M總市值
虧損本益比TTM

Ginkgo Bioworks Holdings Inc

8.405
-0.505-5.67%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-5.67%

5天

+3.77%

1月

-7.74%

6月

-11.15%

今年開始到現在

-14.41%

1年

-12.99%

查看詳細走勢圖

TradingKey Ginkgo Bioworks Holdings Inc股票評分

單位: USD 更新時間: 2025-12-26

操作建議

Ginkgo Bioworks Holdings Inc當前公司基本面數據相對穩定,增長潛力較大。當前估值合理,在生物技術與醫療研究行業排名181/404位。機構持股佔比非常高,近一個月多位分析師給出公司評級為賣出。最高目標價10.67。中期看,股價處於下降通道。近一個月,市場表現較差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Ginkgo Bioworks Holdings Inc評分

相關信息

行業排名
181 / 404
全市場排名
319 / 4563
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
賣出
評級
10.667
目標均價
+13.48%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Ginkgo Bioworks Holdings Inc亮點

亮點風險
Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
估值合理
公司最新PE估值-1.36,處於3年歷史合理位
機構減倉
最新機構持股31.33M股,環比減少0.01%
景順投資公司持倉
明星投資者景順投資公司持倉,最新持倉189.53K股

Ginkgo Bioworks Holdings Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Ginkgo Bioworks Holdings Inc簡介

Ginkgo Bioworks Holdings, Inc. operates as a horizontal platform for cell programming, providing end-to-end services for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Its segments include Cell Engineering and Biosecurity. The Cell Engineering consists of research and development services performed under collaboration and license agreements relating to its cell programming platform. Its cell programming platform includes two core assets: the Foundry, and Codebase. The Biosecurity segment consists of biomonitoring and bioinformatics support services, offered to both government and non-government customers through its two core offerings: Canopy and Horizon. The Company provides comprehensive research and development services spanning the genetic medicine modalities: gene therapy, cell therapy and gene editing, and RNA therapeutics.
公司代碼DNA
公司Ginkgo Bioworks Holdings Inc
CEOKelly (Jason)
網址https://investors.ginkgobioworks.com/

常見問題

Ginkgo Bioworks Holdings Inc(DNA)的當前股價是多少?

Ginkgo Bioworks Holdings Inc(DNA)的當前股價是 8.405。

Ginkgo Bioworks Holdings Inc 的股票代碼是什麼?

Ginkgo Bioworks Holdings Inc的股票代碼是DNA。

Ginkgo Bioworks Holdings Inc股票的52週最高點是多少?

Ginkgo Bioworks Holdings Inc股票的52週最高點是17.580。

Ginkgo Bioworks Holdings Inc股票的52週最低點是多少?

Ginkgo Bioworks Holdings Inc股票的52週最低點是5.000。

Ginkgo Bioworks Holdings Inc的市值是多少?

Ginkgo Bioworks Holdings Inc的市值是477.71M。

Ginkgo Bioworks Holdings Inc的淨利潤是多少?

Ginkgo Bioworks Holdings Inc的淨利潤為-547.03M。

現在Ginkgo Bioworks Holdings Inc(DNA)的股票是買入、持有還是賣出?

根據分析師評級,Ginkgo Bioworks Holdings Inc(DNA)的總體評級為賣出,目標價格為10.667。

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是多少

Ginkgo Bioworks Holdings Inc(DNA)股票的每股收益(EPS TTM)是-6.189。
KeyAI